What should be done for a patient who accidentally took a double dose of long‑acting insulin (e.g., insulin glargine, insulin detemir, insulin degludec) in the morning?

Management of Accidental Double Dose of Long-Acting Insulin

Immediately initiate frequent blood glucose monitoring (every 30 minutes to 1 hour for the first 24 hours) and provide continuous oral carbohydrates or intravenous dextrose infusion to prevent hypoglycemia; the patient will require close observation for 48–96 hours due to the prolonged action of long-acting insulin analogs.

Immediate Actions and Monitoring

Blood Glucose Surveillance

• Check capillary blood glucose every 30 minutes to 1 hour for the first 24 hours, then extend intervals based on stability 1, 2.
• Continue monitoring for 48–96 hours total, as long-acting insulin analogs (glargine, detemir, degludec) have extremely prolonged effects in overdose situations that far exceed their usual duration of action 2, 3.
• Insulin degludec poses particular risk, with a half-life extending to approximately 40 hours after overdose (versus 25 hours at therapeutic doses), potentially causing hypoglycemia lasting over 400 hours 4.

Glucose Replacement Strategy

• Administer continuous intravenous 10% or 20% dextrose infusion if the patient cannot maintain adequate oral intake 2.
• For conscious patients able to eat, provide frequent carbohydrate-containing meals and snacks throughout the monitoring period 1.
• In documented overdose cases, glucose requirements have reached 800 grams per day to prevent hypoglycemia 5.
• Maintain target blood glucose above 100 mg/dL (5.5 mmol/L) during the acute management phase 4.

Risk Stratification by Insulin Type

Insulin Degludec (Tresiba)

• Highest risk for prolonged hypoglycemia due to ultra-long duration of action 4.
• The FDA label specifies that at least 8 hours must elapse between consecutive doses in adults who miss or duplicate doses 6.
• Pediatric patients who accidentally double-dose degludec should contact their healthcare provider immediately and increase monitoring frequency until the next scheduled dose 6.

Insulin Glargine and Detemir

• Overdose effects typically last 48–96 hours, significantly longer than the 24-hour therapeutic duration 2, 3.
• One case report documented glucose infusion requirements for 59 hours after massive glargine overdose 3.

Additional Therapeutic Considerations

Corticosteroid Administration

• Consider hydrocortisone 75 mg every 6 hours for 24 hours if hypoglycemia persists despite adequate glucose replacement 1.
• This approach addresses potential relative adrenal insufficiency and insulin-induced glucose uptake 1, 4.

Surgical Depot Excision

• Surgical excision of the insulin injection site has been successfully performed even days after overdose to remove the subcutaneous insulin depot 2, 5.
• This intervention should be considered when glucose requirements exceed 800 grams per day or when acute hepatic injury develops from massive glucose infusion 5.

Monitoring for Complications

Hepatic Injury

• Monitor liver function tests during treatment, as massive glucose supplementation (>800 g/day) can cause acute hepatic injury 5.
• If transaminases rise significantly, consider earlier surgical depot excision 5.

Hypokalemia

• Monitor serum potassium levels closely, as all insulins shift potassium intracellularly and can cause life-threatening hypokalemia 6.
• This risk is particularly elevated during aggressive glucose and insulin management 6.

Electrolyte Disturbances

• Check electrolytes regularly during the acute phase, as insulin overdose affects multiple electrolyte balances beyond potassium 2.

Common Pitfalls to Avoid

• Do not discontinue glucose supplementation prematurely—the effects of long-acting insulin analogs in overdose far exceed their usual 24-hour duration, and early cessation risks severe rebound hypoglycemia 2, 3.
• Do not rely solely on the patient's usual insulin duration to predict recovery time; overdose pharmacokinetics differ substantially from therapeutic dosing 4.
• Do not assume the patient is safe once initial glucose levels normalize—continued monitoring for 48–96 hours is essential 2.
• Avoid administering the patient's next scheduled basal insulin dose until the overdose effects have completely resolved and glucose levels begin rising spontaneously 6.

Restarting Insulin Therapy

• Once the overdose effects have resolved (typically after 48–96 hours of stable glucose without supplementation), restart basal insulin at 80% of the usual dose to minimize recurrent hypoglycemia risk 6.
• For patients with type 1 diabetes, restart short-acting prandial insulin cautiously with meals, as complete insulin withdrawal risks diabetic ketoacidosis 2.
• Increase monitoring frequency during the transition back to routine insulin therapy 6.